Kim KJ, et al. – This trial dealt with an examination of the correlation between deletion of the HSP110 T17 repeat and expression of wild–type HSP110 (HSP110wt), using DNA testing and immunohistochemistry. It also aimed at identifying the prognostic implications of HSP110 T17 deletion in microsatellite instability–high (MSI–H) advanced gastric cancers (GCs). It was discovered that deletion of the HSP110 T17 repeat was often noted in MSI–H gastric cancers (GCs). The HSP110 T17 deletion size exhibited an inverse link with HSP110wt expression status. Large HSP110 T17 was not a prognostic indicator in MSI–H GCs.